Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · IEX Real-Time Price · USD
3.540
+0.350 (10.97%)
At close: Jul 19, 2024, 4:00 PM
3.590
+0.050 (1.41%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Daré Bioscience Revenue
Daré Bioscience had revenue of $2.82M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $9.30K. In the year 2023, Daré Bioscience had annual revenue of $2.81M.
Revenue (ttm)
$2.82M
Revenue Growth
-71.83%
P/S Ratio
10.59
Revenue / Employee
$108,353
Employees
26
Market Cap
29.82M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
Dec 31, 2022 | 10.00M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
Dec 31, 2012 | 625.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareCloud | 113.02M |
Rapid Micro Biosystems | 23.10M |
Streamline Health Solutions | 21.59M |
Spectral AI | 19.30M |
Evogene | 9.19M |
Lipocine | 4.71M |
Pluri | 341.00K |
DARE News
- 2 days ago - Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewsWire
- 21 days ago - Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - Newsfile Corp
- 24 days ago - Daré Bioscience Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 2 months ago - Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network - GlobeNewsWire
- 2 months ago - Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts - GlobeNewsWire
- 3 months ago - Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - GlobeNewsWire
- 3 months ago - Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive - GlobeNewsWire